CoChat

Robust improvements in fasting and prandial measures of β‐cell function with vildagliptin in drug‐naïve patients: analysis of pooled vildagliptin monotherapy database

Pratley, R. E., Schweizer, A., Rosenstock, J., Foley, J. E., Banerji, M. A., Pi‐Sunyer, F. X., Mills, D., Dejager, S. · 2008 · Diabetes, Obesity and Metabolism
Cited by 65

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Aim: To assess the effects of 24‐week treatment with vildagliptin on measures of β‐cell function in a broad spectrum of drug‐naïve patients with type 2 diabetes (T2DM). Methods: Data from all double‐blind, multicentre, randomized, placebo‐ or active‐controlled trials conducted in drug‐naïve patients with T2DM were pooled from all patients receiving monotherapy with vildagliptin (100 mg daily: 50 mg twice daily or 100 mg once daily, n = 1855) or placebo (n = 347). Fasting measures of β‐cell function [homeostasis model assessment of β‐cell function (HOMA‐B) and proinsulin : insulin ratio] were assessed in the overall pooled monotherapy population. Standard meal tests were performed at baseline and week 24 in a subset of patients, and effects of vildagliptin (100 mg daily, n = 227) on dynamic (meal test–derived) measures of β‐cell function [insulin secretion rate relative to glucose (ISR/G) and insulinogenic indices] were assessed relative to baseline and vs. placebo (n = 29). Results: In the overall population, vildagliptin significantly increased HOMA‐B both relative to baseline [adjusted mean change (AMΔ) = 10.3 ± 1.5] and vs. placebo (between‐treatment difference in AMΔ = 11.5 ± 4.5, p = 0.01) and significantly decreased the proinsulin : insulin ratio relative to baseline (AMΔ = −0.05 ± 0.01) and vs. placebo (between‐treatment difference in AMΔ = −0.09 ± 0.02, p < 0.001). Relative to baseline, vildagliptin monotherapy significantly increased all meal test–derived parameters, and ISR/G (between‐treatment difference in AMΔ = 9.8 ± 2.8 pmol/min/m 2 /mM, p < 0.001) and the insulinogenic index 0–peak glucose (between‐treatment difference in AMΔ = 0.24 ± 0.05 pmol/mmol, p = 0.045) were significantly increased vs. placebo. Conclusions: Vildagliptin monotherapy consistently produced robust improvements in both fasting and meal test–derived measures of β‐cell function across a broad spectrum of drug‐naïve patients with T2DM. All Phase III trials described (NCT 00099905, NCT 00099866, NCT 00099918, NCT 00101673, NCT 00101803 and NCT 00120536) are registered with ClinicalTrials.gov.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2007.00835.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 65

Metadata

Authors
Pratley, R. E., Schweizer, A., Rosenstock, J., Foley, J. E., Banerji, M. A., Pi‐Sunyer, F. X., Mills, D., & Dejager, S.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2008-09-15
Volume
10
Issue
10
Pages
931-938
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2089095955
Cited by
65
References
2
FWCI
6.75
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Robust improvements in fasting and prandial measures of β‐cell function with vildagliptin in drug‐naïve patients: analysis of pooled vildagliptin monotherapy database. https://app.cochat.ai/papers/10.1111/j.1463-1326.2007.00835.x
The paper
Pratley, R. E., Schweizer, A., Rosenstock, J., Foley, J. E., Banerji, M. A., Pi‐Sunyer, F. X., Mills, D., & Dejager, S. (2008). Robust improvements in fasting and prandial measures of β‐cell function with vildagliptin in drug‐naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2007.00835.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.